Vir Biotechnology, Inc.
VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 fā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.78
Price+6.19%
$0.57
1Y
Price
Market Cap
$1.649b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$65.495m
-4.5%
1y CAGR-8.7%
3y CAGR-30.2%
5y CAGREarnings
-$442.717m
-1.1%
1y CAGR+10.1%
3y CAGR-47.3%
5y CAGREPS
-$3.13
+1.0%
1y CAGR+11.7%
3y CAGR-46.2%
5y CAGRBook Value
$812.765m
$1.026b
Assets$212.820m
Liabilities$95.579m
DebtDebt to Assets
9.3%
-0.2x
Debt to EBITDAFree Cash Flow
-$444.812m
-12.1%
1y CAGR+14.6%
3y CAGR-26.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company